These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 26935956)

  • 1. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
    Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
    J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
    Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
    Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.
    Kong Y; Ai C; Dong F; Xia X; Zhao X; Yang C; Kang C; Zhou Y; Zhao Q; Sun X; Wu X
    Cell Cycle; 2018; 17(10):1199-1211. PubMed ID: 29886801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells.
    Ohtaka M; Itoh M; Tohda S
    Anticancer Res; 2017 Nov; 37(11):6047-6053. PubMed ID: 29061784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.
    Nishida Y; Maeda A; Chachad D; Ishizawa J; Qiu YH; Kornblau SM; Kimura S; Andreeff M; Kojima K
    Cancer Sci; 2015 Dec; 106(12):1705-13. PubMed ID: 26450753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
    Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
    Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
    de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
    Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
    Wu SQ; Xu ZZ; Niu WY; Huang HB; Zhan R
    Int J Mol Med; 2014 Aug; 34(2):616-23. PubMed ID: 24913180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.